Overcoming Early Discovery Challenges in Radioligand Therapy Through Imaging-Driven Insights
9:00 am - Wednesday 25th February 2026
- Characterizing biodistribution to guide target and candidate selection, enabling early identification of on-target engagement and minimizing off-target liabilities
- Quantifying dosimetry through direct and surrogate imaging approaches, improving radionuclide choice and translational accuracy of absorbed dose estimates
- Integrating multimodal imaging to monitor treatment response, accelerating proof-of-mechanism insights and data-driven optimization of therapeutic design
New Company for 2026
